ArticleEClinicalMedicine2020

An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19.

Weihui Fu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.